HOME >> MEDICINE >> NEWS
Studies demonstrate positive data in treatment of hepatitis C

BOSTON Data from two ongoing studies testing new approaches for the treatment of chronic hepatitis C will be presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) this afternoon.

Presented by principal investigator Nezam Afdhal, M.D., Chief of Hepatology at Beth Israel Deaconess Medical Center (BIDMC) and Associate Professor of Medicine at Harvard Medical School, the new findings provide researchers with sufficient evidence to demonstrate promising results for hepatitis C patients who have not responded to existing therapies.

A viral infection, hepatitis C is transmitted through exposure to infected blood. The virus, which affects an estimated 4 million individuals nationwide, is able to survive and flourish inside the body by taking up residence in the liver cells, and subsequently using the cells' inner machinery to make more copies of the virus. These in turn, infect other healthy cells.

The standard treatment for hepatitis C is a combination of interferon alfa and ribavirin, which act as anti-viral agents to eradicate the virus. According to Afdhal, the most recent advance in treatment has been the pegylation of interferon, which enables a once- a- week administration of the protein by injection and improves the ability to clear the virus. Combination therapy with pegylated interferon plus ribavirin for 24 to 48 weeks can result in eradication of the virus in about 50 percent of patients, he adds.

"When the hepatitis C virus doesn't respond as occurs in about half of all patients who are treated those patients who already have cirrhosis are at a far greater risk for developing liver cancer or suffering liver failure," notes Afdhal. In fact, he says, hepatitis C is the leading cause of liver transplants in the U.S. Until now, no treatment has been available for these patients.

In his first presentation, Afdhal will describe results from the COPILOT [Colchicine versus PEG-INTRON Long-Term
'"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
1-Nov-2004


Page: 1 2 3

Related medicine news :

1. Studies underscore genetic involvement in nicotine addiction & aggressive hostility
2. Studies address issues of risk and survival in rapidly increasing GI cancers
3. Studies examine coffee drinking and risk of liver and colorectal cancers
4. Studies reveal physicians attitudes on end-of-life care
5. Studies from the November issue of The Archives of Dermatology, a theme issue on facial rejuvenation
6. Studies link obesity to increased frequency of heartburn symptoms; greater risk of esophageal cancer
7. Studies examine risk factors and potential consequences associated with prehypertension
8. Studies show ACTOS(R) (pioglitazone HCl) has positive effects on various components of dyslipidemia
9. Studies identify risk factors for colon cancer
10. Studies indicate healthy eating may affect cancer development, improve digestive system
11. Studies compare hysterectomy vs. other medical treatments for abnormal uterine bleeding

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... , ... July 01, 2020 , ... ... and botanically-derived terpenes, has officially released its new terpene infused product line ... way for consumers to enjoy cannabis terpene profiles and flavors worldwide. , “We’ve ...
(Date:7/1/2020)... ... July 01, 2020 , ... G-CON Manufacturing, the ... by Codiak BioSciences to support its cleanroom build out at its new clinical ... the drug substance and product manufacturing for its clinical pipeline. , Codiak chose ...
(Date:6/28/2020)... ... ... PathAI, a global provider of artificial intelligence (AI)-powered technology for use in ... PD-L1 expression to assess response in patients treated with Bristol Myers Squibb’s PD-1 inhibitor, ... Research (AACR) Annual Meeting. AACR was held June 22 to June 24. , The ...
(Date:6/28/2020)... ... ... The secret of surviving a pandemic with one’s sanity intact does not ... was the first product to disappear off the shelves when the COVID-19 crisis began. ... less need to venture out, the longer you can “survive”. However, does all this ...
(Date:6/25/2020)... ... 2020 , ... Pivot Point Consulting, a national healthcare IT ... its telehealth services to provide end-to-end solutions from strategy to platform ... Magazine “2020 Women Leaders in Technology” award winner, Laura Kreofsky , Advisory ...
Breaking Medicine News(10 mins):
(Date:7/7/2020)... ... , ... Nonprofit Team PHenomenal Hope (Team PH) will announce the 2020 winner ... virtual research town hall on Saturday, July 11 at noon EST. In this virtual ... the area of pulmonary hypertension (PH), in focused talks geared toward the community, and ...
(Date:7/7/2020)... HALIFAX, Nova Scotia (PRWEB) , ... July 07, ... ... 2020 rebrand. Established in 2017, the company began as a hair service provider. ... for both in-office and work-from-home employees. Bright’s expanded offering includes beauty amenities as ...
(Date:7/2/2020)... TAMPA, Fla. (PRWEB) , ... July 02, 2020 , ... ... and fitness professionals, announced that 913,628,072 lifted pounds were logged through its software during ... training in this new age of fitness – an age where even gym giants ...
Breaking Medicine Technology:
Cached News: